Simon Klingler

Simon Klingler

Auto-generated profile, based on publicly available information

Simon Klingler

Department of Chemistry University of Zürich Winterthurerstrasse 190 8057 Zürich Switzerland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
Jason HollandJason Holland
Jason Holland
MGMelanie Gut
Melanie Gut
SKSimon Klingler
Simon Klingler
RFRachael Fay
Rachael Fay
AGAmaury Guillou
Amaury Guillou

8 November 2020 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
RPRoxane Padrutt
Roxane Padrutt
VBVipin Babu
Vipin Babu
SKSimon Klingler
Simon Klingler
MKMartina Kalt
Martina Kalt
FSFrank Schumer
Frank Schumer
Bernhard SpinglerBernhard Spingler
Bernhard Spingler

7 February 2022 in JACS Au
Verified
Journal Article
Open access
DEDaniel F. Earley
Daniel F. Earley
AGAmaury Guillou
Amaury Guillou
SKSimon Klingler
Simon Klingler
RFRachael Fay
Rachael Fay
MGMelanie Gut
Melanie Gut
Jason HollandJason Holland
Jason Holland
The creation of discrete, covalent bonds between a protein and a functional molecule like a drug, fluorophore, or radiolabeled complex is essential for making state-of-the-art tools that find applications in basic science and clinical medicine. Photochemistry offers a unique set of reactive groups that hold potential for the synthesis of protein conjugates. Previous studies have demonstrated that photoactivatable desferrioxamine B (DFO) derivatives featuring a para-substituted aryl azide (ArN3) can be used to produce viable zirconium-89-radiolabeled monoclonal antibodies (89Zr-mAbs) for applications in noninvasive diagnostic positron emission tomography (PET) imaging of cancers. Here, we report on the synthesis, 89Zr-radiochemistry, and light-triggered photoradiosynthesis of 89Zr-labeled human serum albumin (HSA) using a series of 14 different photoactivatable DFO derivatives. The photoactive groups explore a range of substituted, and isomeric ArN3 reagents, as well as derivatives of benzophenone, a para-substituted trifluoromethyl phenyl diazirine, and a tetrazole species. For the compounds studied, efficient photochemical activation occurs inside the UVA-to-visible region of the electromagnetic spectrum (∼365–450 nm) and the photochemical reactions with HSA in water were complete within 15 min under ambient conditions. Under standardized experimental conditions, photoradiosynthesis with compounds 1–14 produced the corresponding 89ZrDFO-PEG3-HSA conjugates with decay-corrected isolated radiochemical yields between 18.1 ± 1.8% and 62.3 ± 3.6%. Extensive density functional theory (DFT) calculations were used to explore the reaction mechanisms and chemoselectivity of the light-induced bimolecular conjugation of compounds 1–14 to protein. The photoactivatable DFO-derivatives operate by at least five distinct mechanisms, each producing a different type of bioconjugate bond. Overall, the experimental and computational work presented here confirms that photochemistry is a viable option for making diverse, functionalized protein conjugates.

13 January 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSimon Klingler
Simon Klingler
Jason HollandJason Holland
Jason Holland
Clinical production of 89Zr-radiolabeled antibodies (89Zr-mAbs) for positron emission tomography imaging relies on the pre-conjugation of desferrioxamine B (DFO) to the purified protein, followed by isolation and characterization of the functionalized intermediate, and then manual radiosynthesis. Although highly successful, this route exposes radiochemists to a potentially large radiation dose and entails several technological and economic hurdles that limit access of 89Zr-mAbs to just a specialist few Nuclear Medicine facilities worldwide. Here, we introduce a fully automated synthesis box that can produce individual doses of 89Zr-mAbs formulated in sterile solution in < 25 min starting from [89Zr(C2O4)4]4– (89Zr-oxalate), our good laboratory practice-compliant photoactivatable desferrioxamine-based chelate (DFO-PEG3-ArN3), and clinical-grade antibodies without the need for pre-purification of protein. The automated steps include neutralization of the 89Zr-oxalate stock, chelate radiolabeling, and light-induced protein conjugation, followed by 89Zr-mAb purification, formulation, and sterile filtration. As proof-of-principle, 89ZrDFO-PEG3-azepin-trastuzumab was synthesized directly from Herceptin in < 25 min with an overall decay-corrected radiochemical yield of 20.1 ± 2.4% (n = 3), a radiochemical purity > 99%, and chemical purity > 99%. The synthesis unit can also produce 89Zr-mAbs via the conventional radiolabeling routes from pre-functionalized DFO-mAbs that are currently used in the clinic. This automated method will improve access to state-of-the-art 89Zr-mAbs at the many Nuclear Medicine and research institutions that require automated devices for radiotracer production.

17 January 2024 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PCPatrick A. Cieslik
Patrick A. Cieslik
SKSimon Klingler
Simon Klingler
MNMirja Nolff
Mirja Nolff
Jason HollandJason Holland
Jason Holland

13 March 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
JGJonas Genz
Jonas Genz
CBCesare Berton
Cesare Berton
SKSamy Kichou
Samy Kichou
SKSimon Klingler
Simon Klingler
Mirja NolffMirja Nolff
Mirja Nolff
Jason HollandJason Holland
Jason Holland
Light-induced bioconjugation and radiolabeling of the cancer-specific monoclonal antibody onartuzumab was accomplished using the tricarbonyl chemistry of the radiotheranostic matched pair of nuclides 99mTc and 188Re.